Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)LeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - Other
Ratios

Amylyx Pharmaceuticals (AMLX) R&D In Process (2024)

Amylyx Pharmaceuticals has reported R&D In Process over the past 1 years, most recently at $36.2 million for Q3 2024.

  • Quarterly results put R&D In Process at $36.2 million for Q3 2024, changed N/A from a year ago — trailing twelve months through Dec 2025 was $36.2 million (changed N/A YoY), and the annual figure for FY2024 was $36.2 million, changed.
  • R&D In Process for Q3 2024 was $36.2 million at Amylyx Pharmaceuticals.
  • Over the last five years, R&D In Process for AMLX hit a ceiling of $36.2 million in Q3 2024 and a floor of $36.2 million in Q3 2024.